Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
The Oncologist|May 7, 2022
Phase II Study of Cabozantinib in Patients With Bone MetastasisEdwin Choy, Gregory M Cote, M Dror Michaelson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancerPhilip J Saylor, Sergey V Kozin, Aya Matsui, et al.
Cancer|March 18, 2014
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinomaDavid Cella, Mellar P Davis, Sylvie Négrier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2014
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigenMaha Hussain, Paul G Corn, M Dror Michaelson, et al.
Cancer|June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapyDaniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
European Urology|April 19, 2021
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell CarcinomaThomas E Hutson, M Dror Michaelson, Timothy M Kuzel, et al.
Clinical Genitourinary Cancer|February 9, 2013
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinibBrian I Rini, Thibault de La Motte Rouge, Andrea L Harzstark, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2017
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)M Dror Michaelson, Chen Hu, Huong T Pham, et al.
The Lancet. Oncology|April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialRobert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Pageof 12